Talent is the first resource for economic and social development, and it is also the most active and positive factor in innovation activities. Practice since Shenzhen’s reform and opening up has repeatedly proved that grasping talents means grasping development, and strong talents mean strong strength. Without talent advantages, it is impossible to have development advantages, innovation advantages, and industrial advantages.
High-level talents play an important supporting role in promoting Shenzhen’s economic and social development. The municipal finance invests no less than 1 billion yuan every year to cultivate and introduce high-level talents and teams at home and abroad. Shenzhen’s emphasis on talents is obvious.
It is reported that high-level talents in Shenzhen include national-level leading talents, local-level leading talents, reserve-level talents and overseas A-, B-, and C-level talents. This time, Hu Junyuan, chairman of Shenzhen Beike Biotechnology Co., Ltd., was rated as a national-level leading talent in Shenzhen.
Dr. Hu Junyuan, chairman of Beike Biotech, holds a PhD in biochemistry and molecular biology from the University of Gothenburg and Chalmers University of Technology in Sweden, a postdoctoral fellow at the University of British Columbia in Canada, a visiting professor at the Department of Surgery at the Chinese University of Hong Kong, and a visiting professor at the Shanghai Cardiovascular Research Institute. He is currently the director of the Shenzhen Stem Cell Engineering Technology Research and Development Center, the vice chairman of the National Stem Cell and Regenerative Medicine Industry Technology Innovation Strategic Alliance, the vice chairman of the China Strategy and Management Research Association, a member of the International Advisory Board of the United Nations Children’s Fund, the executive chairman of the Xiongan International Health Forum, and the chairman of Shenzhen Beike Biotechnology Co., Ltd. has multiple international and domestic patents in the clinical transformation of adult stem cells.
In January 2020, the research results of the Beike Biology team led by Dr. Hu Junyuan“Key technological innovation and clinical application of allogeneic mesenchymal stem cells in the treatment of refractory lupus erythematosus”won 2019 National Technology Invention Award.
In June 2020, a product independently developed by Beike BiotechnologyNew drug clinical registration application for “Injection of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Refractory Systemic Lupus Erythematosus”Officially accepted by the Review Center of the State Food and Drug Administration. The acceptance number is: CXSL2000128. It is reported that this new stem cell drug is the first stem cell product in China for the treatment of refractory systemic lupus erythematosus.